Japanese journal of ophthalmology · 2012
Topical loteprednol etabonate 0.5 % for treatment of vernal keratoconjunctivitis: efficacy and safety.
Сравнительное исследованиеСтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Oner Veysi, Türkcü Fatih Mehmet, Taş Mehmet, Alakuş Mehmet Fuat, Işcan Yalçın
Аннотация
PURPOSE: To evaluate the efficacy and safety of loteprednol etabonate (LE) 0.5 % in vernal keratoconjunctivitis (VKC) patients compared to prednisolone and fluorometholone.
METHODS: The patients were randomized into three groups: the loteprednol group, prednisolone group and fluorometholone group. Medications were administered four times daily, for a total of 28 days. Before starting treatment and at each visit thereafter, the major symptoms and signs of VKC were recorded and graded as 0 (none), 1 (mild), 2 (moderate) or 3 (severe). Adverse event reports including elevation of intraocular pressure (IOP) were recorded.
RESULTS: There were no significant differences among the groups concerning baseline mean scores of signs and symptoms, which gradually improved in all except for pannus formation in the fluorometholone group. However, all signs and symptoms (except for chemosis) were significantly less improved in the eyes of the fluorometholone group compared with the other groups at each control visit. There was significant IOP elevation after the day 3 visit in the prednisolone group only.
CONCLUSION: LE was as effective as prednisolone and more effective than fluorometholone, and it had no side effects during the short-term treatment of VKC patients.
METHODS: The patients were randomized into three groups: the loteprednol group, prednisolone group and fluorometholone group. Medications were administered four times daily, for a total of 28 days. Before starting treatment and at each visit thereafter, the major symptoms and signs of VKC were recorded and graded as 0 (none), 1 (mild), 2 (moderate) or 3 (severe). Adverse event reports including elevation of intraocular pressure (IOP) were recorded.
RESULTS: There were no significant differences among the groups concerning baseline mean scores of signs and symptoms, which gradually improved in all except for pannus formation in the fluorometholone group. However, all signs and symptoms (except for chemosis) were significantly less improved in the eyes of the fluorometholone group compared with the other groups at each control visit. There was significant IOP elevation after the day 3 visit in the prednisolone group only.
CONCLUSION: LE was as effective as prednisolone and more effective than fluorometholone, and it had no side effects during the short-term treatment of VKC patients.